Publication & Citation Trends
Most Cited Works
Publications
236 total
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Cited by 22
Semantic Scholar
IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
Cited by 1
Semantic Scholar
1212P IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
Cited by 0
Semantic Scholar
OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
Cited by 6
Semantic Scholar
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial PDF
Cited by 241
OpenAlex
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Cited by 1,440
OpenAlex
Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial PDF
Cited by 184
OpenAlex
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study PDF
Cited by 570
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(111)
Lung Cancer Research Studies
(39)
Lung Cancer Diagnosis and Treatment
(35)
Occupational and environmental lung diseases
(35)
Cancer Genomics and Diagnostics
(24)
Frequent Co-Authors
Affiliations
University of Pisa
AOL (United States)
University of Cambridge
Cancer Research UK
Cleveland Clinic Lerner College of Medicine